Press releases

28 June, 2018

NeuroVive’s TBI project NeuroSTAT experimental efficacy data published in scientific journal

Lund, Sweden, 28 June 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the traumatic brain injury (TBI) experimental study of NeuroSTAT performed at Univers ...

18 June, 2018

Regulatory

NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma’s new subsidiary Fortify Therapeutics

Lund, Sweden and Palo Alto, Calif., June 18, 2018 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and BridgeBio Pharma today jointly announced that BridgeBio has entered into an ex ...

21 May, 2018

Regulatory

NeuroVive and Yungjin reports positive KL1333 phase I clinical study results paving the way for further clinical development

Lund, Sweden and Seoul, Korea, 21 May 2018 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly an ...

2 May, 2018

NeuroVive initiates collaboration with leading US TBI research organization

Lund, Sweden, 2 May 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced a partnership with TRACK-TBI, a network of US-based world-leading TBI clinicians and researc ...

27 April, 2018

Regulatory

Amendment: Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 27 April 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) (“NeuroVive”) today on 27 April 2018 held its Annual General Meeting (AGM). A summary of the resolutions ...

20 April, 2018

NeuroVive presents NVP025 mitochondrial myopathy project progress at Mitochondrial Medicine conference

Lund, Sweden, 20 April 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that its mitochondrial myopathy project, NVP025, has been selected for an oral presentati ...

20 April, 2018

Regulatory

NeuroVive’s Board Members, Senior Executives and employees will subscribe units in the ongoing rights issue

In the current rights issue in NeuroVive, the Board, Senior Executives and employees have undertaken to subscribe for at least 191,200 units equivalent to MSEK 1.5. The subscription period in [&hellip ...

18 April, 2018

Regulatory

NeuroVive’s KL1333 receives FDA Orphan Drug Designation for treatment of mitochondrial diseases

Lund, Sweden, 18 April 2018 NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that it has been granted Orphan Drug Designation by t ...

17 April, 2018

NeuroVive’s partner Yungjin Pharm completes KL1333 Phase I study recruitment

Lund, Sweden, 17 April 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today announced that the last vi ...

26 March, 2018

Regulatory

Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB

The Board of Directors of NeuroVive Pharmaceutical AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Friday, April 27, 2017, at 10 am at Medicon Village, Scheelevä ...

22 March, 2018

Regulatory

NeuroVive Pharmaceutical AB (publ): report from EGM

Today, 22 March 2018, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company"). A summary of the resolutions follows. All resolutions were passed ...

16 March, 2018

NeuroVive to present at 2nd Annual H.C. Wainwright NASH Investor Conference

Lund, Sweden, 16 March 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that its Chief Medical Officer Magnus Hansson will present the company's non-alcoholic st ...